Drugs / Elritercept
Elritercept
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT07319845 | Apr 2026 → Jun 2028 expected | myelodysplastic syndrome | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT05037760 | Dec 2021 → Feb 2028 expected | myelofibrosis | Takeda | Recruiting | No outcome recorded |
| Phase 2 | NCT04419649 | Aug 2020 → Oct 2029 expected | myelodysplastic syndrome | Takeda | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07623161 | Aug 2026 → Dec 2029 expected | anemia, myelofibrosis | Takeda | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07422480 | May 2026 → Apr 2029 expected | anemia, myelodysplastic syndrome | Takeda | Recruiting | No outcome recorded |
| Phase 3 | NCT06499285 | May 2025 → May 2028 expected | myelodysplastic syndrome | Takeda | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-12-03 | Takeda | Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics takeda.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elritercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06499285 ↗ |
| Known as | ActRIIA/B-Fc | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314737 ↗ |
| Known as | KER-050 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314737 ↗ |
| Known as | KER-050 (ACTRIIA/B-FC) | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314737 ↗ |
| Known as | TAK-226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07319845 ↗ |
| Action | Inhibit | “inhibiting the signaling of a subset of the transforming growth factor beta (TGF-ß) family of proteins” NCT05037760 ↗ |
| Modality | Protein / enzyme biologic | “Elritercept (KER-050) is a recombinant fusion protein” NCT04419649 ↗ |
| Route | Subcutaneous | “Elritercept SC injection.” NCT04419649 ↗ |